Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review
Year: 2026
Type: review
Study design: Systematic Review
Abstract: Jiao Tian,1,2 Yun Zhi Chin,3 Min Hwei Ng,1 Kok Lun Pang,4 Jia Xian Law1 1Department of Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia; 2Department of Clinical Medicine, Zunyi Medical and Pharmaceutical College, Zunyi, Guizhou, People’s Republic of China; 3Division of Applied Biomedical Science and Biotechnology, School of Health Science, IMU University, Kuala Lumpur, Malaysia; 4Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor, MalaysiaCorrespondence: Jia Xian Law, Email [email protected]: Breast cancer is the most prevalent malignancy among women, with triple-negative breast cancer (TNBC) being the most aggressive subtype. The lack of standard targeted therapies necessitates reliance on chemotherapy, which often suffers from poor targeting and significant off-target toxicity. This systematic review evaluates the therapeutic potential of drug delivery systems based on extracellular vesicles (EVs) for TNBC using 17 studies from 2020 to 2024 published in Scopus, PubMed, and Web of Science. The review discusses the diverse therapeutic cargos delivered by EVs, including chemotherapeutic agents and nucleic acids, while emphasizing the need for standardized protocols to facilitate EV isolation and characterization. Key findings provide both in vitro and in vivo evidence of the efficacy of EV-based therapies against TNBC cell lines and animal models, alongside insights into engineering strategies that enhance targeting specificity. Despite the promising findings, challenges remain in clinical translation, such as technical limitations and inconsistent reporting. The results underscore the potential of EVs to revolutionize TNBC treatment strategies, paving the way for more effective therapeutic options.Keywords: exosome, breast cancer, drug delivery system, precision medicine, chemotherapy
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7120655519
FWCI:
Cites:
Cited by:
Related to: